Fig. 5

Validation of the miRNAs’ expression via qRT-PCR and a survival analysis based on miRNAs in tissue samples from HBV-positive HCC patients. a Novel miRNAs including miR-0050-3p, miR-0142-3p, miR-0157-3p, miR-0308-3p, and miR-0233-5p were selected randomly and validated in 15 pairs of HCC patients with or without HBV infection. b miRNAs with overlapping expression patterns, including miR-517a-3p, miR-372-5p, miR-523, miR-522-5p, and miR-524-5p, were selected randomly and validated in 15 pairs of HCC patients with or without HBV infection. c Kaplan–Meier analysis of overall survival based on miR-517a, miR-372, miR-523, miR-522, and miR-324-5p in HBV-positive HCC patients from the TCGA database. Patients with high miR-324-5p expression had a significantly poorer long-term prognosis